| Autor: |
Sarkar S; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Dyett B; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Lakic B; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Ball AS; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Yeo LY; School of Engineering, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., White JF; The Commonwealth Scientific and Industrial Research Organisation, Manufacturing, Clayton, Victoria 3169, Australia., Soni S; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Drummond CJ; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia., Conn CE; School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia. |
| Abstrakt: |
Mycobacterium tuberculosis (MTB) causes the infectious disease tuberculosis (TB), responsible for more deaths than any other single infectious disease in history. Intracellular MTB are slow growing and difficult to target with traditional antitubercular drugs, leading to the emergence of multidrug resistance in TB infection, which is a major global public health issue. Recent advances in innovative lipid nanotechnologies for drug delivery have demonstrated promising outcomes for chronic infectious diseases but have not yet been tested as potential delivery systems for intracellular infections such as TB. The current study evaluates the potential of monoolein (MO)-based cationic cubosomes for the encapsulation and delivery of the first line antitubercular drug rifampicin (RIF) against an MTB-H37Ra in vitro culture model. In particular, we show that the use of cationic cubosomes as delivery vehicles reduced the minimum inhibitory concentration (MIC) of RIF by 2-fold against actively replicating MTB-H37Ra (compared to that of the free drug) and also shortened the lifecycle duration of axenic MTB-H37Ra from 5 to 3 days. The cubosome-mediated delivery was also found to be effective against intracellular MTB-H37Ra within THP-1 human macrophages, with a 2.8 log reduction in viability of the bacilli after 6 days incubation at the MIC. The killing time was also reduced from 8 to 6 days without distressing the host macrophages. Mechanistic studies on the uptake of RIF-loaded cationic cubosomes using total internal reflection fluorescence microscopy (TIRFM) demonstrated the capacity of these lipid particles to effectively target intracellular bacteria. Overall, these results demonstrate that cationic cubosomes are a potent delivery system for the antitubercular drug RIF for therapeutic management of TB. |
